Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/56489
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- IOC - Artigos de Periódicos [12642]
Metadata
Mostrar registro completo
LONGITUDINAL IGG ANTIBODY RESPONSES TO PLASMODIUM VIVAX BLOOD-STAGE ANTIGENS DURING AND AFTER ACUTE VIVAX MALARIA IN INDIVIDUALS LIVING IN THE BRAZILIAN AMAZON
Antígenos de fase sanguínea de Plasmodium vivax
Durante e após malária vivax aguda em indivíduos
Vivendo na amazônia brasileira
To Plasmodium vivax blood-stage antigens
After acute vivax malaria in individuals
Living in the Brazilian Amazon
Autor(es)
Afiliação
Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America / Department of Microbiology and Immunology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom / Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Infectious Diseases and Immune Defence Division, Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Universidade Federal de Juiz de Fora. Instituto de Ciências Biológicas. Departamento de Parasitologia, Microbiologia e Imunologia. Juiz de Fora, MG, Brasil.
Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Parasitologia. São Paulo, SP, Brasil / Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Nova University of Lisbon, Lisbon, Portugal.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia / Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia / Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Infectious Diseases and Immune Defence Division, Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia / Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom / Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Universidade Federal de Juiz de Fora. Instituto de Ciências Biológicas. Departamento de Parasitologia, Microbiologia e Imunologia. Juiz de Fora, MG, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America / Department of Microbiology and Immunology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America / Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom / Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Infectious Diseases and Immune Defence Division, Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Universidade Federal de Juiz de Fora. Instituto de Ciências Biológicas. Departamento de Parasitologia, Microbiologia e Imunologia. Juiz de Fora, MG, Brasil.
Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Parasitologia. São Paulo, SP, Brasil / Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Nova University of Lisbon, Lisbon, Portugal.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia / Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia / Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Infectious Diseases and Immune Defence Division, Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia / Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom / Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Universidade Federal de Juiz de Fora. Instituto de Ciências Biológicas. Departamento de Parasitologia, Microbiologia e Imunologia. Juiz de Fora, MG, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America / Department of Microbiology and Immunology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America / Ryan White Center for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Resumo em Inglês
Background
To make progress towards malaria elimination, a highly effective vaccine targeting Plasmodium
vivax is urgently needed. Evaluating the kinetics of natural antibody responses to vaccine
candidate antigens after acute vivax malaria can inform the design of serological
markers of exposure and vaccines.
Methodology/Principal findings
The responses of IgG antibodies to 9 P. vivax vaccine candidate antigens were evaluated in
longitudinal serum samples from Brazilian individuals collected at the time of acute vivax
malaria and 30, 60, and 180 days afterwards. Antigen-specific IgG correlations, seroprevalence,
and half-lives were determined for each antigen using the longitudinal data. Antibody
reactivities against Pv41 and PVX_081550 strongly correlated with each other at each of
the four time points. The analysis identified robust responses in terms of magnitude and seroprevalence against Pv41 and PvGAMA at 30 and 60 days. Among the 8 P. vivax antigens demonstrating >50% seropositivity across all individuals, antibodies specific to
PVX_081550 had the longest half-life (100 days; 95% CI, 83–130 days), followed by
PvRBP2b (91 days; 95% CI, 76–110 days) and Pv12 (82 days; 95% CI, 64–110 days).
Palavras-chave
Respostas longitudinais de anticorpos IgGAntígenos de fase sanguínea de Plasmodium vivax
Durante e após malária vivax aguda em indivíduos
Vivendo na amazônia brasileira
Palavras-chave em inglês
Longitudinal IgG antibody responsesTo Plasmodium vivax blood-stage antigens
After acute vivax malaria in individuals
Living in the Brazilian Amazon
Compartilhar